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Abstract 
Background: To determine whether C-reactive protein (CRP) is an inflammatory biomarker that may 
identify patients at risk of infections or death. Mortality among HIV-infected persons commencing 
antiretroviral therapy (ART) is often attributed to tuberculosis (TB) or bloodstream infections (BSI). 
Methods: In two district hospitals in southern Malawi we recruited HIV-infected adults with one or 
more unexplained symptoms present for at least one month (weight loss, fever, or diarrhea), and 
negative expectorated sputum microscopy for TB. CRP determination for 452/469 (96 %) partici-
pants at study enrolment was analyzed for associations with TB, BSI or death to 120 days post-
enrolment. 
Results: Baseline CRP was significantly elevated among patients with confirmed and probable TB 
(52), BSI (50) or death (60) compared to those with no identified infection who survived at least 120 
days (269). A CRP value of >10 mg/L was associated with confirmed and probable TB (adjusted odds 
ratio 5.7; 95% CI 2.6, 14.3; 87% sensitivity) or death by 30 days (adjusted odds ratio 9.2; 95% CI 2.2, 
55.1; 88% sensitivity). CRP was independently associated with TB, BSI or Death but prediction of the-
se endpoints was enhanced by including hemoglobin (all outcomes), CD4 count (BSI, death), and 
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whether ART was started (death) in logistic regression models.  
Conclusion: High CRP at the time of ART initiation is associated with TB, BSI and early mortality, and 
so has potential utility for stratifying patients for intensified clinical and laboratory investigation and 
follow-up. They may also be considered for empirical treatment of opportunistic infections including 
TB. 
 
Keywords: C-reactive protein, HIV, tuberculosis, biomarker, bloodstream infection, risk of death 
 
Introduction 
Early mortality among HIV-infected persons initiating ART in sub-Saharan African settings is signifi-
cantly higher than that observed in treatment cohorts in well-resourced settings.1 Several studies of 
febrile hospitalized patients, as well as autopsy studies, have shown tuberculosis (TB) to be a major 
cause of morbidity and mortality.2-5 Bloodstream infections (BSI) are also well-documented in this 
population.6, 7 Given the limited capacity for clinical assessment to detect or rule out TB, BSI or risk of 
death, there is considerable interest in the evaluation of host biomarkers which could predict the 
presence of latent or active TB, and risk of death,8-11 12, 13including the non-specific biomarker C-
reactive protein (CRP). 
 CRP elevation has been documented in relation to a wide range of inflammatory conditions, 
both infectious and non-infectious. It is known to be elevated in active TB, bacterial and fungal infec-
tions, and to fall with treatment of TB and other infections; 14 elevated CRP (>10 mg/L) predicts dis-
ease-specific and all-cause mortality risk among HIV-infected persons. 10, 15 Although CRP elevation is 
relatively nonspecific, a low or normal CRP (<5 or <8 mg/L, depending on the assay) has been evalu-
ated as a test to rule out active TB, with negative predictive values for bacteriologically-confirmed TB 
of 96% reported for a cohort of HIV-positive outpatients being investigated for TB disease after self-
presenting with symptoms. 16 In Gugulethu Township near Cape Town, South Africa, however, CRP 
lacked diagnostic utility in a cohort of patients due to start ART, with all but a few participants having 
moderately raised CRP irrespective of final TB diagnosis.17 
 We have previously reported results from a cohort of patients recruited from two HIV clinics 
in Malawi in 2010 who were starting ART as outpatients with smear-negative WHO-stage 3/4 dis-
ease, for whom we identified a high risk of BSI (mainly non-typhoidal Salmonella), TB and death.18 
The main aim of the current study from this same cohort was to describe the utility of CRP, and to 
investigate positive and negative predictive values of CRP relating to TB, BSI and death. 
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Methods 
Study design 
As part of a prospective observational cohort study18 investigating the prevalence of TB and BSI 
among expectorated sputum smear-negative, HIV-infected persons qualifying for ART on the basis of 
chronic non-specific symptoms (detailed below), venous blood was collected at the time of study en-
rolment for later CRP determination (post-study).  Infections (case definitions are provided below) 
and deaths retrospectively diagnosed up to 120 days post-enrolment were used for the analysis pre-
sented here.  
 
Ethics 
This study received ethics approval from the National Health Sciences Research Committee, Lilong-
we, Malawi, and from the Ethics Advisory Group of the International Union Against Tuberculosis and 
Lung Disease, Paris, France (IUATLD). 
 
Study population 
HIV-infected adults (≥ 15 years of age is considered adult in the Malawi health system) undergoing 
assessment for initiation of ART, or seeking health care in outpatient clinics, were consecutively re-
cruited at Zomba Central Hospital and Thyolo District Hospital, in southern Malawi between Febru-
ary and November 2010. Patients were eligible for study enrolment if they had three negative expec-
torated sputum smears (or were unable to expectorate sputum) and fulfilled at least one of the fol-
lowing criteria: history of unexplained weight loss >10% of baseline body weight (estimated or 
measured), or unexplained fever (intermittent or continuous) for >1 month duration, or unexplained 
diarrhea >1 month in duration, or weight loss <10% of baseline body weight but with CD4 count 
<250 cells/microliter. Anti-TB therapy in the past month or pregnancy were exclusion criteria. The 
study population for this analysis consisted of 452 participants with an enrolment CRP value availa-
ble. 
 
Enrolment and follow-up procedures 
Eligible patients provided written (or witnessed thumbprint if illiterate) informed consent before en-
rolment, or assent with written informed consent from the guardian for the (one) participant under 
18 years of age.  
 A baseline interview included questions on demographics, clinical history and current symp-
toms. Weight and height were recorded.  Blood was taken for full blood count, culture into Myco/F 
Lytic™ (supportive of mycobacterial as well as standard bacterial growth), cryptococcal antigen (latex 
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agglutination test), CD4 count, and CRP assay.  A single induced sputum specimen was collected for 
high quality microscopy after specimen concentration, and mycobacterial solid culture. 
 A chest radiograph was obtained if not already available. Participants were then managed 
under the routine care system at each hospital, but with the benefit of results provided by the study 
team, except for CRP (which was measured only post-study). Xpert MTB/Rif was not available at the 
time of this study. A comprehensive description of the parent study and its procedures is available. 18 
 
Clinical endpoints 
Participants were enrolled in the study only if they had initial negative routine expectorated sputum 
smears or if they were unable to expectorate. Additional study diagnostics included sputum induc-
tion and concentration of induced sputum for acid-fast bacilli staining and mycobacterial culture.  
 Confirmed TB:  1 positive M. tuberculosis culture (sputum and/or blood); probable TB: 1 
positive (induced, concentrated) sputum smear, but negative or contaminated culture results; possi-
ble TB: decision to start anti-TB therapy despite negative bacteriological results, or without culture.  
For this analysis, possible TB cases were included if treatment was started within 60 days of enrol-
ment and no other BSI was identified on the enrolment blood culture. 
 Bloodstream infection (BSI): pathogenic species isolated from blood culture taken at the 
time of study enrolment, or a serum cryptococcal antigen titre of 1:10 (considered to be evidence 
of disseminated cryptococcal infection). 
 Death was determined by report of participants’ relatives or guardian and/or tracing of par-
ticipants lost to follow-up. 19 
 
Laboratory methods 
These have been described in detail in an earlier paper as follows. 18 TB microscopy and cultures 
were performed at the TB laboratory of the College of Medicine/Malawi-Liverpool-Wellcome Trust 
Clinical Research Programme (MLW), Blantyre. This laboratory provides TB diagnostic support to 
clinical trials funded by the National Institutes of Health, Division of AIDS (NIH/DAIDS)/AIDS Clinical 
Trials Group (ACTG) and as such employs the quality management system recommended by the NIH, 
including an annual audit. The laboratory takes part in the External Quality Assurance programs of 
both the NIH and the UK National External Quality Assurance Scheme (NEQAS). 
 After same-day transport to the laboratory, induced sputum (IS) was decontaminated with 
an equal volume of 4% NaOH for 15 minutes and concentrated with centrifugation before culture 
onto Lowenstein-Jensen (LJ) media for up to eight weeks. Smears made from both direct and con-
centrated sputum were examined under fluorescent microscopy (Auramine O), with any positive re-
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sults confirmed by Ziehl-Neelsen staining (ZN). Mycobacterial isolates were further speciated as My-
cobacterium tuberculosis (MTB) or nontuberculous mycobacteria (NTM) using microscopic cording 
and MBP-64 lateral flow assays (Capilia®; TAUNS Laboratories, Inc., Numazu, Japan) and, if either 
test was negative, growth on media with p-nitrobenzoic acid (PNB) at room temperature and/or 45 
deg C. 
 Blood for culture of mycobacteria and other bacterial (or fungal) pathogens was collected 
using a sterile technique and transferred the same day to the Microbiology Laboratory at Queen 
Elizabeth Hospital, Blantyre (supported by the Malawi-Liverpool-Wellcome Trust Clinical Research 
Programme). For bacterial culture, venous blood (5–7.5 mL) was taken for aerobic culture in 50 mL 
of broth and incubated for 7 days (BacT/ALERT 3D®; bioMérieux SA, Marcy l’Etoile, France). Isolates 
were then identified using standard diagnostic techniques. For the purpose of this study, all organ-
isms which are found as normal skin or oral flora were considered to be contaminants, including co-
agulase-negative Staphylococci, alpha-hemolytic Streptococci other than S. pneumoniae, and 
diphtheroids. Antibiotic susceptibility was determined by disc testing (Oxoid, Cambridge, UK). 
 For mycobacterial culture, venous blood (5 mL) was inoculated into 50 mL broth (BACTEC 
Myco/F Lytic®; Becton Dickinson Microbiology Systems, Sparks, MD, USA) and incubated at 37 oC. 
Bottles were inspected daily for the first 14 days and then once every 2 days using a handheld UV 
Woods lamp. Contents of bottles were concentrated by centrifugation (3000 g for 15 minutes) either 
within 48 hours after first detection of fluorescence, or at the end of 6 weeks' incubation (whichever 
occurred sooner). The concentrate was examined with ZN and Gram’s staining to exclude bacterial 
contaminants, and subcultured onto LJ media. ZN positive subcultures were then speciated as 
above.  
 Cryptococcal antigen tests were conducted on a single 1∶10 dilution of serum using a Cryp-
tococcus rapid latex agglutination test (Oxoid, Cambridge, UK).  
 CRP measurements were performed using CRP latex (Beckman Coulter, Brea, USA) after 
study completion on thawed plasma (collected at the time of study enrolment and frozen at -20˚C) 
by personnel without knowledge of microbiological test results, to exclude any influence on clinical 
decision-making. The assay provided CRP values in the range of 3.0 to 480 mg/L. 
 
Statistical analysis  
Median/IQR was used to summarize continuous variables. Wilcoxon rank sum tests were used to 
test the equality of the distribution of two continuous random variables. Binomial logistic regression 
was used to evaluate the relative contribution of CRP and other variables (with known biological as-
sociations to the outcomes) to the prediction of each of TB, BSI or death, stated as odds ratios for a 
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10-unit increase in CRP, with 95% CI’s and P-values for each. Final multivariable logistic regression 
models were constructed based on the results of the bivariate binomial logistic regression modelling. 
Sample size was chosen for the parent study of TB prevalence. In accordance with STARD (Standards 
for Reporting Diagnostic Accuracy) guidelines, 20 sensitivity and specificity of CRP as a classifier of 
each of TB, BSI and death, respectively, were estimated. We present sensitivity and specificity when 
the CRP cut-off point is set to 10 mg/L (the justification for this cut-off point is provided in Results). 
Binomial confidence intervals are calculated for sensitivity and specificity. We also estimated ROC 
(receiver operating characteristic) curves plotting estimated sensitivities and specificities at various 
CRP cut-off points. We estimated AUC (area under the curve) for the corresponding ROC curves (see 
Figures, Supplemental Digital Content 1, 2, 3 and 4, showing ROC curves for CRP in relation to TB 
(confirmed or probable), BSI, Death by 30 days, and Death by 120 days, respectively). Levels of signif-
icance were set at 5%.  
 
Results 
Of 469 participants (279 female) enrolled in the parent study, 452 had a CRP value obtained at the 
time of study enrolment for this analysis (Figure 1). The median CD4 count was 128 cells /microliter 
(IQR 48-214). Study participants reported chronic fever (62.4%), weight loss >10% of baseline body 
weight (53%), and/or chronic diarrhea (35%); 68% of participants reported >1 of these inclusion cri-
teria. There were 48 confirmed TB cases, 4 probable TB cases, 48 possible TB cases and 50 blood-
stream infections (29 non-typhoidal Salmonella, 5 E. coli, 4 other pathogenic bacteria, 8 C. 
neoformans, and 4 non-tuberculous mycobacteria). Participants with confirmed or probable TB (but 
not possible TB), or BSI, or who died within 120 days of study enrolment had significantly higher 
baseline CRP values than participants with no infection who survived >120 days post-enrolment (all 
paired comparisons p < 0.01, except for ‘possible TB’ compared to ‘no death or infection’ which was 
non-significant, p 0.7,) (Figure 2). 
 Binary logistic regression with CRP as a continuous variable confirmed that CRP level was 
significantly associated with confirmed & probable TB (but not possible TB), BSI and death by 30, 60, 
90 and 120 days from enrolment (not shown).  
 Various specific threshold values of CRP were evaluated for their potential predictive value 
as a part of baseline screening at the time of assessment for ART enrolment.  A cut off value of CRP 
>10 mg/L demonstrated both strong associations with each of the outcomes of interest, with mini-
mal compromise of sensitivity (although low specificity of 50.9%) (Table 1). This cut off point is con-
sistent with that used in previous studies of CRP8, 10 and with the usual definition of elevated CRP in 
clinical medicine.21, 22 
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 To determine the relative predictive contribution of CRP, binary logistic regression was used 
to evaluate several other predictor variables with a plausible biological association with each out-
come of interest.  Final logistic regression models for confirmed & probable TB, and BSI included 
CRP, CD4 category (<50, 50-200, with reference category >200 cells/microL), and severe anemia 
(Hemoglobin <8 g/dL); logistic regression models for death by 30, 60, 90 and 120 days included CRP, 
CD4 category, severe anemia, and use of ART (Table 2). Results for death by 60 and 90 days are not 
shown. We are not attempting to build a rigorous predictive model (for any of the 3 outcomes) but 
rather seeking to illustrate the relative contributions of other major risk factors in combination with 
elevated CRP. 
 To explore the use of CRP in combination with other commonly available baseline predic-
tors, the composite probability of TB, BSI and Death was estimated using multivariable logistic re-
gression with various combinations of dichotomized predictor variables (Table 3). 
 
Discussion 
This study demonstrates that baseline CRP elevation is independently associated with increased risk 
of confirmed and probable TB, BSI or death among chronically ill, HIV-infected participants.  
 It has been shown previously that when examining various threshold values of CRP for their 
utility in predicting TB, sensitivity is lost and specificity improved at successively higher CRP values.17 
We evaluated various threshold values and found associations for CRP >10 mg/L with confirmed and 
probable TB (OR = 5.7; 95% CI 2.6, 14.3) that retained moderately high sensitivity (87%), although 
with low specificity (51%), despite negative routine sputum smear microscopy for TB. When CRP ex-
ceeded this threshold and severe anemia was also present the probability of confirmed or probable 
TB was as high as 37% in this setting of high TB prevalence, compared to <5% if neither risk factor 
was present. The association of TB with baseline CRP > 10 mg/L and anemia among ART initiators 
was observed by Shivakoti et al.13 As previously observed by Lawn et al,8 CRP was not associated with 
CD4 count in TB patients. 
 CRP elevation was not associated with possible TB, which were cases defined on clinical 
grounds (with or without radiological evidence) but without laboratory evidence for the diagnosis. 
The lack of association may reflect misdiagnosis of non-TB cases, which is inevitable (but difficult to 
quantify) in a context where the sensitivity of the TB diagnostic methods was limited (this study was 
conducted before the introduction of Xpert MTB/Rif), and where smear-negative pulmonary TB is 
commonplace. CRP values are thought to correlate with bacillary burden. 14, 16 It is possible that true 
TB cases with a very low bacillary burden in sputum (such that they were smear and culture negative 
on single sputum culture) may not demonstrate the inflammatory response typically seen to M. tu-
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berculosis, and that CRP values were consequently lower in these cases. We are unable to resolve 
this conundrum in this analysis. 
 The more modest, although significant, association between CRP rise and BSI may have re-
sulted because some BSI cases present in a clinically subtle manner, with few signs of systemic in-
flammation typically associated with CRP elevation. This may be explained by impairment of the in-
flammatory response in the context of HIV infection; previous analysis of this cohort showed no as-
sociation of fever with non-typhoidal Salmonella (NTS) BSI. 18The majority (29/50, 58%) of the path-
ogenic (non-TB) isolates in this study were NTS; 8 others were Cryptococcus neoformans infections. 
These WHO clinical stage 4 infections are associated with low CD4 counts so it is not surprising that 
CD4 counts were associated with BSI in this population, as previously demonstrated. As with TB, the 
coexistence of severe anemia markedly increased the probability of BSI. 
 The strongest performance by CRP was in the prediction of risk of death. As a clinical end-
point death has the advantage of capturing all of the participants with diagnosed or undiagnosed but 
ultimately fatal infections. The association of baseline CRP elevation with all-cause risk of death is 
well known 23, 24 and our analysis illustrates that this association is durably present at 30, 60, 90 and 
120 days after enrolment. Nonetheless, the strength of the association is notably higher for death by 
30 days, where participants with CRP >10 mg/L had a 9-fold risk of death compared to those with 
lower CRP values. Higher CRP thresholds offered no advantage in terms of the strength of associa-
tion with death, or sensitivity which was 88% for the threshold CRP value of >10 mg/L.  
 Participants who failed to start ART had the strongest probability of death at any interval, 
among the predictor variables we studied. Among such patients the presence of the 3 other risk fac-
tors (CRP >10, severe anemia, CD4 <200) yielded a 96% probability of death by 30 days.  If ART was 
started the probability of death by 30 days fell to 13.4% despite the presence of the other 3 poor 
prognostic factors at baseline, underscoring the importance of urgent ART initiation – even for pa-
tients with CD4 >200 among whom the probability of 30 day mortality was 72% if CRP was >10 mg/L 
and severe anemia was present. Unlike the baseline risk factors, ART initiation is clearly within pro-
grammatic control. All patients in this study were ART eligible even according to the 2010 WHO ART 
guidelines but the urgency of starting ART may not have been recognized. 
 Baseline CRP could potentially be used in clinical screening of HIV-infected patients with 
negative routine sputum smear microscopy in various ways. Although we have shown moderately 
high sensitivity for the prediction of death or TB, it would be unreasonable to expect high specificity 
from a non-specific inflammatory biomarker. The greatest utility of CRP will therefore be to use its 
sensitivity for risk stratification in combination with other risk factors, rather than in making a specif-
ic diagnosis. Since a CRP value above 10 mg/L identifies patients with a comparatively high risk of 
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death by 30 days (PPV 0.15; 95% CI 0.10-0.21)(NPV 0.98; 95% CI 0.94-0.99), and of confirmed & 
probable TB (PPV 0.25; 95% CI 0.19-0.33)(NPV 0.95; 95% CI 0.90-0.98) and BSI (PPV 0.21; 95% CI 
0.15-0.28)(NPV 0.90 95% CI 0.84-0.94), it could be used to identify patients who deserve to be more 
carefully and frequently evaluated both clinically and with higher sensitivity TB diagnostic tools 
(Xpert MTB/Rif) and blood cultures, and to ensure there are no unintended delays in ART initiation, 
particularly if hemoglobin and CD4 count are also available for risk stratification. Empirical anti-TB 
treatment or BSI treatment could be considered case-by-case, but would ideally be evaluated in clin-
ical trials. Inpatient versus outpatient management could be evaluated. 
 The potential for baseline CRP to be used as a ‘rule out’ test to exclude (or at least predict 
very low risk for) TB, BSI or risk of death was evaluated using a CRP threshold of ≤3 mg/L. A baseline 
CRP value at or below this level would have correctly predicted the absence of confirmed & probable 
TB in 94% of cases, but would have missed 6% of cases. The problem with this threshold value is that 
the median CRP was 9.6 mg/L for participants who did not die or have TB by 120 days – so only a mi-
nority of patients had CRP <3 mg/L. This shortcoming, also noted by Lawn et al 17, limits the practical 
use of CRP for ruling out TB.  
 
Limitations 
We were able to perform blood and induced sputum cultures only once, at the time of study enrol-
ment, so it was not possible to microbiologically verify any infections arising after enrolment. Bacte-
remia may have been missed by a single culture and we were unable to exclude use of antibiotics (or 
other agents that could modulate the inflammatory response) prior to study enrolment. We em-
ployed a single solid media TB culture of sputum, which can be expected to detect roughly half of all 
potentially culture positive TB that would be detected with 3 liquid media TB cultures.25 Many cases 
that were not culture positive are likely to have been diagnosed on clinical (and possibly radiological) 
grounds, but we have no way of ascertaining what proportion of possible TB cases identified in this 
study would have been sputum culture positive, or positive by molecular testing, in an ideal setting. 
This may have resulted in some unintentional misclassification of TB cases and non-cases that would 
tend to diminish differences between these groups. Our choice of a comparator group of patients 
without identified infection and surviving to at least 120 days was intended to ensure that the com-
parator group was very unlikely to contain undiagnosed TB cases. It is possible that there were undi-
agnosed TB cases in the group that died by 120 days but this would not alter our interpretation of 
the results related to risk of death. 
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Conclusion 
Among chronically ill, WHO Stage 3 & 4 HIV-infected patients with negative routine sputum smear 
microscopy, baseline CRP > 10 mg/L may offer a simple means of identifying individuals at higher risk 
of death and of TB, and the need for intensified investigation and clinical follow-up. Further research 
could evaluate the utility of CRP screening among all HIV-infected persons (regardless of symptoms), 
and the effectiveness of empiric treatments based on CRP elevations. 
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Figure Legend 
Figure 1: Participant flow diagram* (figures shown for confirmed or probable TB)  
The reference standard for confirmed or probable TB is described above in Methods. Diagnosis of 
confirmed or probable TB was categorized as Inconclusive if any of the following conditions were 
met: possible TB diagnosis (no laboratory evidence), death at <120 days from enrolment with no in-
fection or with a non-TB bloodstream infection diagnosed. Confirmed or probable TB was catego-
rized as Absent if no infection was diagnosed and the subject survived to at least 120 days post-
enrolment. 
*Format as stipulated in STARD 201520 
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Tables 
Table 1: Sensitivity and specificity, and positive and negative predictive values of various CRP cut-
off values for TB, BSI and Death by 30 days 
CRP (mg/L) CRP>3 CRP>5 CRP>10 CRP>20 CRP>50 
Confirmed 
or Proba-
ble TB 
Sens 0.88 
(0.77, 0.96) 
0.88 
(0.77, 0.96) 
0.87 
(0.74, 0.94) 
0.79 
(0.65, 0.89) 
0.52 
(0.37, 0.66) 
Spec 0.33 
(0.28, 0.40) 
0.40 
(0.34, 0.46) 
0.51 
(0.45, 0.57) 
0.62 
(0.56, 0.68) 
0.79 
(0.73, 0.84) 
PPV 0.21 
(0.15, 0.26) 
0.22 
(0.17, 0.29) 
0.25 
(0.19, 0.33) 
0.28 
(0.21, 0.37) 
0.32 
(0.22, 0.43) 
NPV 0.94 
(0.87, 0.98) 
0.95 
(0.89, 0.98) 
0.95 
(0.90, 0.98) 
0.94 
(0.89, 0.97) 
0.89 
(0.85, 0.93) 
BSI Sens 0.82 
(0.69, 0.91) 
0.80 
(0.66, 0.90) 
0.70 
(0.55, 0.82) 
0.60 
(0.45, 0.74) 
0.32 
(0.20, 0.47) 
Spec 0.33 
(0.28, 0.40) 
0.40 
(0.34, 0.46) 
0.51 
(0.45, 0.57) 
0.62 
(0.56, 0.68) 
0.79 
(0.73, 0.84) 
PPV 0.19 
(0.14, 0.25) 
0.20 
(0.15, 0.26) 
0.21 
(0.15, 0.28) 
0.23 
(0.16, 0.31) 
0.22 
(0.13, 0.33) 
NPV 0.91 
(0.84, 0.96) 
0.92 
(0.85, 0.96) 
0.90 
(0.84, 0.94) 
0.89 
(0.84, 0.93) 
0.86 
(0.81, 0.90) 
Death by 
30 days 
Sens 0.88 
(0.70, 0.98) 
0.88 
(0.70, 0.98) 
0.88 
(0.70, 0.98) 
0.88 
(0.70, 0.98) 
0.77 
(0.56, 0.91) 
Spec 0.34 
(0.28, 0.40) 
0.40 
(0.34, 0.46) 
0.51 
(0.45, 0.57) 
0.62 
(0.56, 0.68) 
0.79 
(0.73, 0.84) 
PPV 0.11 
(0.07,0.17) 
0.13 
(0.08, 0.18) 
0.15 
(0.10, 0.21) 
0.18 
(0.12, 0.26) 
0.26 
(0.17, 0.37) 
NPV 0.97 
(0.91, 0.99) 
0.97 
(0.89, 0.99) 
0.98 
(0.94, 0.99) 
0.98 
(0.95, 0.99) 
0.97 
(0.94, 0.99) 
Figures in brackets are 95% confidence intervals for proportion above 
Sens = Sensitivity; Spec = Specificity; PPV = Positive Predictive Value; NPV = Negative Predictive Value 
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Table 2: Odds Ratios (adjusted) for clinical endpoints with multivariable logistic regression 
Confirmed & Probable TB Adjusted OR (95% CI) p-value 
CRP>10 5.7 (2.6-14.3) <0.001 
Severe Anemia 2.3 (1.2-4.6) 0.016 
CD4 <50 1.2 (0.5-2.8) 0.729 
CD4 50-200 0.9 (0.4-2.0) 0.847 
BSI Adjusted OR (95% CI) p-value 
CRP>10 2.1 (1.1-4.2) 0.037 
Severe Anemia 2.3 (1.1-4.7) 0.020 
CD4 <50 5.1 (2.0-14.5) 0.001 
CD4 50-200 1.8 (0.7-5.2) 0.212 
Death by 30 days Adjusted OR (95% CI) p-value 
CRP>10 9.2 (2.2-55.1)  0.006 
Severe Anemia 11.6 (3.4-50.6) <0.001 
CD4 <50 6.8 (1.0-53.8) 0.057 
CD4 50-200 9.6 (2.1-54.9) 0.006 
ART not taken 142.9 (31.2-970.9) <0.001 
Death by 120 days Adjusted OR (95% CI) p-value 
CRP>10 2.9 (1.4-6.4) 0.005 
Severe Anemia 3.6 (1.8-7.4) <0.001 
CD4 <50 5.2(1.83-15.9) 0.003 
CD4 50-200 4.8 (1.9-13.2) 0.002 
ART not taken 18.0 (8.0-44.1) <0.001 
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Table 3: Probability of clinical endpoint with selected combinations of dichotomized risk factors 
CRP >10 mg/L Severe Anemia   Confirmed & Probable TB 
(95% CI)* 
Yes Yes - - 37% (21-57) 
Yes No - - 21 % (12-33) 
No No - - 4% (2-10) 
CRP >10 mg/L Severe Anemia CD4 <200  BSI (95% CI)** 
Yes Yes Yes - 35% (23-50) 
No Yes Yes - 21% (11-37) 
Yes No Yes - 20% (14-29) 
Yes Yes No - 16% (7-35) 
No No No - 4% (2-10) 
CRP >10 mg/L Severe Anemia CD4 <200 ART not started Death by 30 days (95% 
CI)*** 
Yes Yes Yes Yes 96% (81-99) 
Yes Yes No Yes 72% (42-90) 
No Yes Yes Yes 70% (27-93) 
Yes No Yes Yes 65% (35-87) 
Yes Yes Yes No 13% (5-29) 
No No No No <<1% (0-<1) 
 
*Cohort prevalence of confirmed or probable TB 52/371 (16.2%); (censored: possible TB cases, 
deaths to 120 days where confirmed/probable TB or BSI was not diagnosed) 
**Cohort prevalence of BSI 50/371 (15.7%); (censored: possible TB cases, deaths to 120 days where 
confirmed/probable TB or BSI was not diagnosed) 
***Overall 30-day mortality risk was 26/418 (6.2%); (censored: deaths >30 days but ≤120 days) 
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